14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CDTX ranks #15159 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cidara Therapeutics Stock Forecast NASDAQ:CDTX

$0.84 (1.32%)

Volume: 231k

Closed: Jan 25, 2022

Hollow Logo Score: -4.315

Cidara Therapeutics Stock Forecast

$0.84 (1.32%)

Volume: 231k

Closed: Jan 25, 2022

Score Hollow Logo -4.315

Cidara Therapeutics Company Profile

6310 Nancy Ridge Drive

San Diego CA 92121



Industry: Biotechnology

Sector: Healthcare

Cidara Therapeutics


Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease, as well as engages in evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal pathogen. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE